Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) Research & Development (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Research & Development readings, the most recent being $9000.0 for Q2 2025.

  • On a quarterly basis, Research & Development fell 10.0% to $9000.0 in Q2 2025 year-over-year; TTM through Dec 2025 was $9000.0, a 83.02% decrease, with the full-year FY2025 number at $9000.0, down 83.02% from a year prior.
  • Research & Development hit $9000.0 in Q2 2025 for Arcadia Biosciences, down from $13000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.2 million in Q1 2021 to a low of $6000.0 in Q1 2024.
  • Median Research & Development over the past 5 years was $255000.0 (2022), compared with a mean of $345294.1.
  • The widest YoY moves for Research & Development: up 60.0% in 2024, down 98.33% in 2024.
  • Arcadia Biosciences' Research & Development stood at $561000.0 in 2021, then decreased by 10.87% to $500000.0 in 2022, then crashed by 98.2% to $9000.0 in 2023, then skyrocketed by 44.44% to $13000.0 in 2024, then crashed by 30.77% to $9000.0 in 2025.
  • The last three reported values for Research & Development were $9000.0 (Q2 2025), $13000.0 (Q4 2024), and $24000.0 (Q3 2024) per Business Quant data.